Overview

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years

Status:
Terminated

Trial end date:
2019-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, randomised phase 3b clinical trial of Imatinib 400 to 800 mg daily versus Nilotinib 300 mg two times daily in chronic phase CML patients with confirmed MMR without MR4.5

Phase:

Phase 3

Details

Lead Sponsor:

Prof. Dr. Nikolas von Bubnoff

Collaborator:

Novartis

Treatments:

Imatinib Mesylate